Accelerate the completion of round B financing of RMB 300 million

[enterprise news of China Pharmaceutical network] kangfang biology announced the completion of round B financing of 300 million yuan After this round of financing, the company will continue to work with domestic and foreign pharmaceutical enterprises in various forms of strategic cooperation to rapidly market the independently developed antibody new drugs from the drug discovery stage (accelerating the completion of round B financing of RMB 300 million by kangfang biology to the sea photo source: 123rf Gallery) kangfang biology, an innovative drug R & D enterprise, announced the completion of round B financing of RMB 300 million Gaotejia investment group led the investment, Shenzhen innovation investment group, former shareholder Qianhai master fund and Qianhai Qinzhi capital jointly participated in the investment, and Huaxing capital acted as the financial consultant This round of financing will support kangfang biology to carry out international and domestic clinical research of several innovative antibody products, promote pre clinical research of research projects, and start the construction of new drug production base of the company Kangfang biology, headquartered in Zhongshan City, Guangdong Province, is an innovative biopharmaceutical company based in the health industry base It was founded in 2012 by four overseas returnees, focusing on the development of innovative antibody new drugs with independent intellectual property rights In July 2015, kangfang Bio Technology Co., Ltd obtained 150 million yuan a round financing jointly funded by Shenzhen innovation investment group, Zhongshan xunxiang capital, Shanghai Jianxin capital and Shenzhen Qianhai Xinnuo Kangfang Bio said that the a round financing will be used to rapidly promote the existing R & D product line of antibody new drugs to clinical research In the past two years, the company has established 25 new antibody product lines, covering major diseases such as tumors, autoimmune diseases, cardiovascular diseases, inflammation, metabolic diseases and pain It is understood that kangfang biology is an innovative biomedical enterprise that authorizes new monoclonal antibody drugs developed independently to global pharmaceutical giants Kangfang biology has the core antibody research and development ability, especially the unique tetrabody bispecific antibody development technology At the same time, the company has a whole process development platform from early research and development to pilot test and production of antibodies In November of the same year, kangfang biology and mosadong reached a cooperation on the research, development and promotion of ak107, a monoclonal antibody drug for tumor immunotherapy MSD will obtain the global development and promotion right of ak-107, and kangfang biology will receive a preliminary payment from MSD, as well as a phased payment with a total price of US $200 million covering development and promotion According to the data reported by the biological products circle, on January 1, 2016 and February 2017, there was no gain in the approval of domestic antibodies and no new batch of imported products Despite the strong development of the global antibody drug industry, domestic enterprises are still in the back of the track compared with developed countries such as Europe, America and Japan in many aspects such as the creation of new antibody drugs, product types, etc After this round of financing, the company will continue to cooperate with domestic and foreign pharmaceutical enterprises in various forms in the future, and jointly promote the independently developed antibody new drugs to the market from the drug discovery stage Xia Yu, founder, chairman and CEO of kangfang biology, said that kangfang biology will continue to strengthen R & D and innovation, and develop high-quality antibody drugs affordable to patients around the world " Original title: speed up going to sea, promote the marketization of new antibody drugs, kangfang biology completed a round B financing of 300 million yuan Author: Wu Dan